1. Advances in Immunotherapy for Hepatocellular Carcinoma
   Satoru Hagiwara et al, 2023, Cancers CrossRef
2. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models
   Natsumi Kawasaki et al, 2023, Leukemia & Lymphoma CrossRef
3. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
   Takuya Sho et al, 2022, Cancers CrossRef
4. Inducing vascular normalization: A promising strategy for immunotherapy
   Xin Luo et al, 2022, International Immunopharmacology CrossRef
5. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
   Alberto Giuseppe Agostara et al, 2023, Expert Review of Respiratory Medicine CrossRef
6. Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
   Zijian Yang et al, 2023, Cancers CrossRef
7. Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1
   Maria Anele Romeo et al, 2023, Discover Oncology CrossRef
8. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
   Christopher Tay et al, 2023, Cancer Cell CrossRef